by Jim Stallard,Memorial Sloan Kettering Cancer CenterCredit: Pixabay/CC0 Public DomainMantle cell lymphoma (MCL) is a rare and sometimes ruthless form of non-Hodgkin lymphoma. Even when treatme
byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainAs novel cancer treatments continually emerge, it is essential to collect data on patients' quality of life along wit
byUniversity of California, Los AngelesCredit: MART PRODUCTION from PexelsUCLA researchers have developed a deep-learning framework that teaches itself quickly to automatically analyze and diagn
Wearable brain imaging device shines a light on how babies respond in real-world situationsbyUniversity College LondonMother Mererid and baby Mabli were volunteers in the study. Credit: Liam Col
Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
byETH ZurichCredit: CC0 Public DomainShould I go and exercise, or would I rather go to the café and enjoy a delectable strawberry milkshake? Until now, what exactly happens in our brain when we
byETH ZurichCredit: CC0 Public DomainShould I go and exercise, or would I rather go to the café and enjoy a delectable strawberry milkshake? Until now, what exactly happens in our brain when we
In a significant leap forward for dental care, Boston-based company Perceptive has announced the completion of the world's first fully automated dental procedure on a human.
In a significant leap forward for dental care, Boston-based company Perceptive has announced the completion of the world's first fully automated dental procedure on a human.
The Prix Galien is often regarded as the equivalent of the Nobel Prize in biopharmaceutical research, highlighting its significance in the scientific community.
The Prix Galien is often regarded as the equivalent of the Nobel Prize in biopharmaceutical research, highlighting its significance in the scientific community.
The U.S. Food and Drug Administration (FDA) had approved Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
The U.S. Food and Drug Administration (FDA) had approved Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
byKing's College LondonCredit: Unsplash/CC0 Public DomainAutomated insulin delivery systems have, for the first time, been tested for people with type-one diabetes and end-stage kidney disea
Wearable brain imaging device shines a light on how babies respond in real-world situationsbyUniversity College LondonMother Mererid and baby Mabli were volunteers in the study. Credit: Liam Col
by Jim Stallard,Memorial Sloan Kettering Cancer CenterCredit: Pixabay/CC0 Public DomainMantle cell lymphoma (MCL) is a rare and sometimes ruthless form of non-Hodgkin lymphoma. Even when treatme
byNIH/National Human Genome Research InstituteNIH researchers and collaborators have found that being a carrier for sickle cell disease, known as having sickle cell trait, increases the risk of
byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainAs novel cancer treatments continually emerge, it is essential to collect data on patients' quality of life along wit
Announcement of the 2024 Nobel Prize in Physiology or Medicine Nobel Prize in Physiology or Medicine...Announcement of the 2024 Nobel Prize in ChemistryThe Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry 2024 with one half to David Baker, University of Was...AlphaFold: The making of a scientific breakthroughThe inside story of the DeepMind team of scientists and engineers who created AlphaFold, an AI system that is recognised as a solution to "p...